EGFR and non-small cell lung carcinoma: Preliminary results obtained from the TATTON study revealed that osimertinib combined with selumetinib exhibited an ORR of 42% and a median DOR of 16.6 months with a manageable toxicity profile in EGFR-mutated NSCLC patients whose disease progressed on a previous EGFR-TKI [134].